Deerfield Management Company, L.P. (Series C) Uni Qure N.V. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2018 Feb 14, 2019	SELL	$22.8 - $33.93 $5.5 Million - $8.19 Million	-241,430 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$29.75 - $43.08 $7.18 Million - $10.4 Million	241,430 New	241,430 $8.79 Million

Others Institutions Holding QURE

# of Institutions

153

Shares Held

41M

Call Options Held

925K

Put Options Held

617K

Vestal Point Capital, LP New York, NY

4.75M
Shares

$27.5 Million
1.78% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

2.78M
Shares

$16.1 Million
0.81% of portfolio
Boxer Capital, LLC San Diego, CA

2.23M
Shares

$12.9 Million
0.58% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.19M
Shares

$12.7 Million
0.01% of portfolio
Abrdn PLC

1.93M
Shares

$11.1 Million
0.02% of portfolio

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account